Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy

Background: Carfilzomib, the proteasome inhibitor, can increase the overall survival rate of multiple myeloma (MM) patients undergoing targeted therapy. However, relapse and toxicity present great challenges for such treatment, so an urgent need for effective combination therapy is necessary. Emodin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chin-Mu, Yen, Chia-Hung, Wang, Shu-Chen, Liu, Yi-Chang, Huang, Chien-Tzu, Wang, Min-Hong, Chuang, Tzer-Ming, Ke, Ya-Lun, Yeh, Tsung-Jang, Gau, Yuh-Ching, Du, Jeng-Shiun, Wang, Hui-Ching, Cho, Shih-Feng, Tsai, Yuhsin, Hsiao, Chi-En, Hsiao, Samuel Yien, Hsiao, Hui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312579/
https://www.ncbi.nlm.nih.gov/pubmed/35884943
http://dx.doi.org/10.3390/biomedicines10071638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312579/
https://www.ncbi.nlm.nih.gov/pubmed/35884943
http://dx.doi.org/10.3390/biomedicines10071638

Ejemplares similares